In this study, we will evaluate the effectiveness of several doses of oral selenomethionine in raising biomarkers of selenium status including plasma selenium concentrations.
Results of studies with animal tumor models and human clinical trials suggest that the essential nutrient selenium can be anti-tumorigenic if consumed at levels greater than nutritional requirements. If it is possible to increase plasma selenium concentrations above 120 nanograms per milliliter with less than 200 micrograms of selenium daily, then it is possible that supplementation can be accomplished through the use of selenium-containing foods.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
262
daily placebo capsules for 12 months
daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
USDA Grand Forks Human Nutrition Research Center
Grand Forks, North Dakota, United States
Evaluation of effectiveness of consuming oral doses of L-selenomethionine in raising plasma selenium concentrations
Time frame: Baseline, and after 3, 6, 9, and 12 months of supplementation
Biomarkers of selenium status will be determined in urine, buccal cells, and plasma. White blood cells will be analyzed to identify DNA damage, reflecting the degree of oxidative damage and evaluate the status of antioxidant repair mechanisms.
Time frame: Baseline and after 12 months of supplementation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.